Altimmune, Inc. (ALT)
ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer
LAS VEGAS, NV / ACCESSWIRE / August 26, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech leader specializing in blockchain-powered technologies for digital asset management, is pleased to announce the appointment of Peter Tassiopoulos as Chief Executive Officer. Concurrently, Tony Issac will transition to the role of President while continuing as Chairman of the Board.
ALT 5 Sigma to Exhibit at SiGMA Budapest September 2-4, 2024
LAS VEGAS, NV / ACCESSWIRE / August 23, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced their participation in the upcoming SiGMA Budapest show. ALT5 will be exhibiting through the 3 days of the show at the Hungexpo Budapest Congress and Exhibition Centre Hall E providing product demonstrations, solutions and general information to many of the 17,000+ attendees starting September 2nd in booth B133.
ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024
Q2 Fintech results only include the period commencing May 15, 2024, the date on which the ALT 5 Sigma acquisition closed, to June 30, 2024 LAS VEGAS, NV / ACCESSWIRE / August 19, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced financial results for its second fiscal quarter ended June 29, 2024. Fiscal Second Quarter 2024 Key Highlights- Fintech Revenues of $2.17 million (for the period from May 15 to June 29) Gross Profit of $1.1 million or 51% Net income from continuing operations of $589 thousand, as compared to $79 thousand for the same period last fiscal year Net income per basic and diluted common share of $0.07, as compared to $0.02 for the same period last fiscal year for continuing operations and $0.01 for discontinued operations Cash and cash equivalents of $5.75 million Stockholders' equity of $22.9 million "We are very pleased with the performance of ALT5 Sigma, particularly considering that our Q2 results reflect only about 45 days of combined operations since the transaction was completed mid-quarter," stated Tony Issac, CEO of ALT5 Sigma.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.
ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024
LAS VEGAS, NV / ACCESSWIRE / August 13, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for July 2024. According to the company, ALT5's transaction volume exceeded US$179 million for the month of July 2024, which represents a year-over-year increase of 114% from the $84 million recorded in July 2023.
The 7 Best Under $10 Stocks to Buy in August 2024
To understand the allure of buying the best stocks under $10, it's a good idea to go back to basics. A stock's price reflects how much you pay for one dollar of a company's earnings.
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors-Altimmune Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Andrew Shutterly - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Liam Hiester - Piper Sandler Seema Sheoran - Evercore Omari Baruti - Goldman Sachs William Wood - B. Riley Securities Jon Wolleben - Citizens JMP Operator Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Second Quarter 2024 Financial Results Conference Call.
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Weight loss treatments such as Ozempic, Wegovy, Mounjaro, and Zepbound are big players in the diabetes and obesity care markets. One risk of losing weight is shedding too much muscle mass.
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The weight loss space is dominated by Eli Lilly and Novo Nordisk, which produce the leading medications. Viking Therapeutics, Altimmune, Pfizer, and Roche are all looking to enter the red-hot weight loss space.
ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024
LAS VEGAS, NV / ACCESSWIRE / July 25, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for Q1 and Q2 2024 combined. According to the company, ALT5's transaction volume reached US$879 million for the first two quarters of 2024, ending June 30, 2024, which represents a year-over-year increase of 99%.
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Eli Lilly and Novo Nordisk will need to share the weight-loss drugs market someday. Altimmune's candidate looks like it could succeed where their medicines struggle.
3 Undervalued Biotech Stocks With Breakout Potential
Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies.
